Designed SARS-CoV-2 receptor binding domain variants form stable monomers
© 2022 The Authors. Biotechnology Journal published by Wiley-VCH GmbH..
The receptor binding domain (RBD) of the SARS-CoV-2 spike (S)-protein is a prime target of virus-neutralizing antibodies present in convalescent sera of COVID-19 patients and thus is considered a key antigen for immunosurveillance studies and vaccine development. Although recombinant expression of RBD has been achieved in several eukaryotic systems, mammalian cells have proven particularly useful. The authors aimed to optimize RBD produced in HEK293-6E cells towards a stable homogeneous preparation and addressed its O-glycosylation as well as the unpaired cysteine residue 538 in the widely used RBD (319-541) sequence. The authors found that an intact O-glycosylation site at T323 is highly relevant for the expression and maintenance of RBD as a monomer. Furthermore, it was shown that deletion or substitution of the unpaired cysteine residue C538 reduces the intrinsic propensity of RBD to form oligomeric aggregates, concomitant with an increased yield of the monomeric form of the protein. Bead-based and enzyme-linked immunosorbent assays utilizing these optimized RBD variants displayed excellent performance with respect to the specific detection of even low levels of SARS-CoV-2 antibodies in convalescent sera. Hence, these RBD variants could be instrumental for the further development of serological SARS-CoV-2 tests and inform the design of RBD-based vaccine candidates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Biotechnology journal - 17(2022), 5 vom: 28. Mai, Seite e2100422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klausberger, Miriam [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.05.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/biot.202100422 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336127278 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336127278 | ||
| 003 | DE-627 | ||
| 005 | 20231225231430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/biot.202100422 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336127278 | ||
| 035 | |a (NLM)35078277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klausberger, Miriam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Designed SARS-CoV-2 receptor binding domain variants form stable monomers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Biotechnology Journal published by Wiley-VCH GmbH. | ||
| 520 | |a The receptor binding domain (RBD) of the SARS-CoV-2 spike (S)-protein is a prime target of virus-neutralizing antibodies present in convalescent sera of COVID-19 patients and thus is considered a key antigen for immunosurveillance studies and vaccine development. Although recombinant expression of RBD has been achieved in several eukaryotic systems, mammalian cells have proven particularly useful. The authors aimed to optimize RBD produced in HEK293-6E cells towards a stable homogeneous preparation and addressed its O-glycosylation as well as the unpaired cysteine residue 538 in the widely used RBD (319-541) sequence. The authors found that an intact O-glycosylation site at T323 is highly relevant for the expression and maintenance of RBD as a monomer. Furthermore, it was shown that deletion or substitution of the unpaired cysteine residue C538 reduces the intrinsic propensity of RBD to form oligomeric aggregates, concomitant with an increased yield of the monomeric form of the protein. Bead-based and enzyme-linked immunosorbent assays utilizing these optimized RBD variants displayed excellent performance with respect to the specific detection of even low levels of SARS-CoV-2 antibodies in convalescent sera. Hence, these RBD variants could be instrumental for the further development of serological SARS-CoV-2 tests and inform the design of RBD-based vaccine candidates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antibody assay validation | |
| 650 | 4 | |a antigen stability | |
| 650 | 4 | |a receptor binding domain | |
| 650 | 4 | |a recombinant expression | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Cysteine |2 NLM | |
| 650 | 7 | |a K848JZ4886 |2 NLM | |
| 700 | 1 | |a Kienzl, Nikolaus F |e verfasserin |4 aut | |
| 700 | 1 | |a Stadlmayr, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Grünwald-Gruber, Clemens |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Stadlbauer, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Stracke, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Vierlinger, Klemens |e verfasserin |4 aut | |
| 700 | 1 | |a Hofner, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Manhart, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Gerner, Wilhelm |e verfasserin |4 aut | |
| 700 | 1 | |a Grebien, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Weinhäusel, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Mach, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Wozniak-Knopp, Gordana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnology journal |d 2006 |g 17(2022), 5 vom: 28. Mai, Seite e2100422 |w (DE-627)NLM164618910 |x 1860-7314 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:5 |g day:28 |g month:05 |g pages:e2100422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/biot.202100422 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 5 |b 28 |c 05 |h e2100422 | ||